GENMAB AS DK 1 | 346.40 / -0.09% |
News
- Notice to Convene the Annual General Meeting of Genmab A/S
02/24/2022 / 12:01 - GlobeNewswire - Genmab Publishes 2021 Annual Report
02/16/2022 / 17:00 - GlobeNewswire - Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
01/25/2022 / 12:30 - GlobeNewswire - Genmab Announces Financial Results for the First Nine Months of 2021
11/10/2021 / 17:00 - GlobeNewswire - Genmab Improves its 2021 Financial Guidance
11/04/2021 / 21:24 - GlobeNewswire - Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
10/19/2021 / 12:29 - GlobeNewswire - Capital Increase in Genmab as a Result of Employee Warrant Exercise
09/21/2021 / 20:22 - GlobeNewswire - Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
09/20/2021 / 23:00 - GlobeNewswire - Genmab Announces Financial Results for the First Half of 2021
08/11/2021 / 17:01 - GlobeNewswire - Major Shareholder Announcement
07/21/2021 / 18:58 - GlobeNewswire - Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
07/21/2021 / 12:31 - GlobeNewswire - Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
06/22/2021 / 16:12 - GlobeNewswire - Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
05/21/2021 / 15:08 - GlobeNewswire - Genmab Announces Financial Results for the First Quarter of 2021
05/05/2021 / 17:01 - GlobeNewswire - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
04/20/2021 / 12:34 - GlobeNewswire